ReviewCNS drugs2011
Managing suicide risk in patients with schizophrenia.
Review in CNS drugs, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 134 citations in OpenAlex.
- Interpersonal beliefs related to suicide and facial emotion processing in psychotic disorders.Journal of psychiatric research · 2018Trial
- Using telehealth to augment an intensive case monitoring program in veterans with schizophrenia and suicidal ideation: A pilot trial.Psychiatry research · 2016Trial
- Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data.Schizophrenia research · 2015Trial
- What is behind the 17-year life expectancy gap between individuals with schizophrenia and the general population?Schizophrenia (Heidelberg, Germany) · 2025Article
- Effectiveness of antipsychotic medication in patients with schizophrenia in a real world retrospective observational study in Ethiopia.Scientific reports · 2025Observational
- Clozapine, relapse, and adverse events: a 10-year electronic cohort study in Canada.The British journal of psychiatry : the journal of mental science · 2024Article
- Sleep Problems, Suicidal Ideation, and Psychopathology in First-Episode Psychosis.Schizophrenia bulletin · 2024Article
- Enhancing Predictive Power: Integrating a Linear Support Vector Classifier with Logistic Regression for Patient Outcome Prognosis in Virtual Reality Therapy for Treatment-Resistant Schizophrenia.Journal of personalized medicine · 2023Article
- Understanding the Association Between Mental Health Knowledge and Mental Health Service Utilization Among Black Adults.Community mental health journal · 2023Article
- Depression Mediates the Relationships between Hallucinations, Delusions, and Social Isolation in First-Episode Psychosis.Social work research · 2022Article
- You lack the season of all natures, sleep.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2022Article
- Insomnia and suicide as reported adverse effects of second-generation antipsychotics and mood stabilizers.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2022Article
- The role of psychological autopsy in investigating a case of atypical suicide in schizophrenia: a case report with a brief review of literature.Egyptian journal of forensic sciences · 2022Article
- Telomere Length as a Marker of Suicidal Risk in Schizophrenia.Consortium psychiatricum · 2022Article
- An exploratory magnetic resonance imaging study of suicidal ideation in individuals at clinical high-risk for psychosis.Psychiatry research. Neuroimaging · 2021Article
- Effectiveness of Antipsychotics in Reducing Suicidal Ideation: Possible Physiologic Mechanisms.Healthcare (Basel, Switzerland) · 2021Article
- Comparative Effectiveness of Antipsychotics for Risk of Attempted or Completed Suicide Among Persons With Schizophrenia.Schizophrenia bulletin · 2021Article
- The Importance of Suicide Risk Formulation in Schizophrenia.Frontiers in psychiatry · 2021Review
- Comparison of Suicide Risk by Mental Illness: a Retrospective Review of 14-Year Electronic Medical Records.Journal of Korean medical science · 2020Article
- Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety-Particularities in the Context of COVID-19.Brain sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
The management of suicide risk in patients with schizophrenia poses many challenges for clinicians. Compared with the general population, these patients have an 8.5-fold greater risk of suicide. This article reviews the literature dealing with the treatment of at-risk patients with schizophrenia. An integrated psychosocial and pharmacological approach to managing this population of patients is recommended. Although there is at least modest evidence suggesting that antipsychotic medications protect against suicidal risk, the evidence appears to be most favourable for second-generation antipsychotics, particularly clozapine, which is the only medication approved by the US FDA for preventing suicide in patients with schizophrenia. In addition, treating depressive symptoms in patients with schizophrenia is an important component of suicide risk reduction. While selective serotonin receptor inhibitors (SSRIs) ameliorate depressive symptoms in patients with schizophrenia, they also appear to attenuate suicidal thoughts. Further research is needed to more effectively personalize the treatment of suicidal thoughts and behaviours and the prevention of suicide in patients with schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.